Rivista e Edizione

Volume 72 (2022): Edizione 4 (December 2022)

Volume 72 (2022): Edizione 3 (September 2022)

Volume 72 (2022): Edizione 2 (June 2022)

Volume 72 (2022): Edizione 1 (March 2022)

Volume 71 (2021): Edizione 4 (December 2021)

Volume 71 (2021): Edizione 3 (September 2021)

Volume 71 (2021): Edizione 2 (June 2021)

Volume 71 (2021): Edizione 1 (March 2021)

Volume 70 (2020): Edizione 4 (December 2020)

Volume 70 (2020): Edizione 3 (September 2020)

Volume 70 (2020): Edizione 2 (June 2020)

Volume 70 (2020): Edizione 1 (March 2020)

Volume 69 (2019): Edizione 4 (December 2019)

Volume 69 (2019): Edizione 3 (September 2019)

Volume 69 (2019): Edizione 2 (June 2019)

Volume 69 (2019): Edizione 1 (March 2019)

Volume 68 (2018): Edizione 4 (December 2018)

Volume 68 (2018): Edizione 3 (September 2018)

Volume 68 (2018): Edizione 2 (June 2018)

Volume 68 (2018): Edizione 1 (March 2018)

Volume 67 (2017): Edizione 4 (December 2017)

Volume 67 (2017): Edizione 3 (September 2017)

Volume 67 (2017): Edizione 2 (June 2017)

Volume 67 (2017): Edizione 1 (March 2017)

Volume 66 (2016): Edizione 4 (December 2016)

Volume 66 (2016): Edizione 3 (September 2016)

Volume 66 (2016): Edizione 2 (June 2016)

Volume 66 (2016): Edizione 1 (March 2016)

Volume 65 (2015): Edizione 4 (December 2015)

Volume 65 (2015): Edizione 3 (September 2015)

Volume 65 (2015): Edizione 2 (June 2015)

Volume 65 (2015): Edizione 1 (March 2015)

Volume 64 (2014): Edizione 4 (December 2014)

Volume 64 (2014): Edizione 3 (September 2014)

Volume 64 (2014): Edizione 2 (June 2014)

Volume 64 (2014): Edizione 1 (March 2014)

Volume 63 (2013): Edizione 4 (December 2013)

Volume 63 (2013): Edizione 3 (September 2013)

Volume 63 (2013): Edizione 2 (June 2013)

Volume 63 (2013): Edizione 1 (March 2013)

Volume 62 (2012): Edizione 4 (December 2012)

Volume 62 (2012): Edizione 3 (September 2012)

Volume 62 (2012): Edizione 2 (June 2012)

Volume 62 (2012): Edizione 1 (March 2012)

Volume 61 (2011): Edizione 4 (December 2011)

Volume 61 (2011): Edizione 3 (September 2011)

Volume 61 (2011): Edizione 2 (June 2011)

Volume 61 (2011): Edizione 1 (March 2011)

Volume 60 (2010): Edizione 4 (December 2010)

Volume 60 (2010): Edizione 3 (September 2010)

Volume 60 (2010): Edizione 2 (June 2010)

Volume 60 (2010): Edizione 1 (March 2010)

Volume 59 (2009): Edizione 4 (December 2009)

Volume 59 (2009): Edizione 3 (September 2009)

Volume 59 (2009): Edizione 2 (June 2009)

Volume 59 (2009): Edizione 1 (March 2009)

Volume 58 (2008): Edizione 4 (December 2008)

Volume 58 (2008): Edizione 3 (September 2008)

Volume 58 (2008): Edizione 2 (June 2008)

Volume 58 (2008): Edizione 1 (March 2008)

Volume 57 (2007): Edizione 4 (December 2007)

Volume 57 (2007): Edizione 3 (September 2007)

Volume 57 (2007): Edizione 2 (June 2007)

Volume 57 (2007): Edizione 1 (March 2007)

Dettagli della rivista
Formato
Rivista
eISSN
1846-9558
Pubblicato per la prima volta
28 Feb 2007
Periodo di pubblicazione
4 volte all'anno
Lingue
Inglese

Cerca

Volume 69 (2019): Edizione 1 (March 2019)

Dettagli della rivista
Formato
Rivista
eISSN
1846-9558
Pubblicato per la prima volta
28 Feb 2007
Periodo di pubblicazione
4 volte all'anno
Lingue
Inglese

Cerca

10 Articoli
Accesso libero

Pancreatic lipase inhibitory activity of selected pharmaceutical agents

Pubblicato online: 07 Dec 2018
Pagine: 1 - 16

Astratto

Abstract

Twenty-five structurally diverse compounds have been tested in vitro for their pancreatic lipase (PL) inhibitory activity. Despite the diversity of tested compounds, the relationship comprising structural attributes of the compounds could be established to correlate with the observed inhibitory activity. Compounds that exerted inhibitory action through surface activity were of different profile from the rest of compounds. When co-incubated with orlistat (OsT), important synergistic effects for some compounds (orphenadrine, gliclazide, cefuroxime and sulfacetamide) were revealed, while antagonistic effects were demonstrated for others (camphor sulfonic acid and dinitro salicylic acid). Docking studies for the most active molecules were performed and molecular interaction forces with the PL active site were identified. The results suggested co-binding of OsT along with the other inhibitor in the binding site in cases of synergistic effect but not in the case of antagonistic effect. These results were additionally supported by affinity capillary electrophoresis. In conclusion, synergistic lipase inhibitory activity between OsT and some other pharmaceutical compounds was demonstrated for the first time, which might help improve the pharmacological effect of OsT.

Parole chiave

  • pancreatic lipase
  • pancreatic lipase inhibitory test
  • pharmaceutical compounds
  • affinity capillary electrophoresis
  • docking studies
Accesso libero

Solubilization of ibuprofen for freeze dried parenteral dosage forms

Pubblicato online: 07 Dec 2018
Pagine: 17 - 32

Astratto

Abstract

Ibuprofen, a weakly acidic non-steroidal anti-inflammatory drug having poor aqueous solubility, is a challenging drug for the development of pharmaceutical formulations, resulting in numerous research attempts focusing on improvement of its solubility and consequently bioavailability. Most studies have been done for solid dosage forms, with very little attention paid to parenterals. Hence, the main purpose of the present study was to enhance ibuprofen solubility as a result of formulation composition and the freeze drying process. Moreover, the purpose was to prepare a freeze dried dosage form with improved ibuprofen solubility that could, after simple reconstitution with water for injection, result in an isotonic parenteral solution. Solubility of ibuprofen was modified by various excipients suitable for parenteral application. Drug interactions with selected excipients in the final product/lyophilisate were studied by a combined use of XRPD, DSC, Raman and ss-NMR. Analyses of lyophilized samples showed solubility enhancement of ibuprofen and in situ formation of an ibuprofen salt with the alkaline excipients used.

Parole chiave

  • ibuprofen
  • solubility enhancement
  • freeze drying
  • physicochemical characterization
Accesso libero

Therapeutic bullfrog oil-based nanoemulsion for oral application: Development, characterization and stability

Pubblicato online: 07 Dec 2018
Pagine: 33 - 48

Astratto

Abstract

The aim of this study was to develop, optimize, and characterize a stable therapeutic bullfrog oil based nanoemulsion for oral application using a rational experimental design approach. The optimized oral nanoemulsion contained 0.2 % sodium benzoate and 0.02 % propyl-paraben as preservatives; 0.1 % sucralose and 0.4 % acesulfam K as sweeteners and 0.1 % tutti-frutti as flavoring to mask the unpleasant organoleptic characteristics of bullfrog oil. The oral O/W-nanoemulsion showed the droplet size, PDI, zeta potential, and pH of 410 ± 8 nm, 0.20 ± 0.02, –38 ± 2.5 mV, and 6.43 ± 0.05, respectively. The optimized oral nanoemulsion showed a milky single-phase and optimal physical stability at 25 °C for 90 days. Indeed, higher oxidation induction time and lower formation of peroxides in the oral nanoemulsion were responsible for improving its stability. A therapeutic delivery system containing bullfrog oil for oral application was successfully developed and optimized with ideal thermo-oxidative stability.

Parole chiave

  • bullfrog oil
  • nanoemulsion
  • thermo-oxidative stability
  • experimental design
  • oral application
  • therapeutic nanosystem
Accesso libero

Dendrimer functionalized folate-targeted gold nanoparticles for luciferase gene silencing in vitro: A proof of principle study

Pubblicato online: 07 Dec 2018
Pagine: 49 - 61

Astratto

Abstract

Use of exogenous small interfering RNA (siRNA) has shown potential in gene silencing. The need for target-specific siRNA delivery vehicles is crucial to successful gene silencing. This study is aimed at developing and evaluating the safety and efficiency of siRNA delivery using unmodified and folic acid (FA) modified poly(amidoamine) generation 5 (PAMAM G5D) functionalized gold nanoparticles (Au:G5D/Au:G5D:FA) in vitro. All formulations were physico--chemically characterized and nanocomplexes were evaluated using the band shift, dye displacement, nuclease protection, MTT cell viability, and luciferase reporter gene assays. Nanocomplexes bound and protected siRNA against degrading RNases, and were well tolerated by the cells. The Au:G5D:FA nanocomplexes elicited excellent gene silencing in folate receptor expressing HeLa-Tat-Luc cells, decreasing significantly in the presence of excess FA ligand, indicating nanocomplex uptake by the mechanism of receptor mediation. These results highlight the synergistic role played by Au and the dendrimer in enhancement of transgene silencing.

Parole chiave

  • siRNA
  • gold nanoparticles
  • dendrimers
  • folic acid
  • gene silencing
Accesso libero

Identification of new process-related impurity in the key intermediate in the synthesis of TCV-116

Pubblicato online: 07 Dec 2018
Pagine: 63 - 74

Astratto

Abstract

Development of safe and effective drugs requires complete impurity evaluation and, therefore, knowledge about the formation and elimination of impurities is necessary. During impurity profiling of a key intermediate during synthesis of candesartan cilexetil (1-(((cyclohexyloxy)carbonyl) oxy)ethyl 1-((2’-(2H-tetrazol-5-yl)-[1,1’-biphenyl]-4-yl) methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate, TCV-116), a novel compound, which had not been reported previously, was observed. Structural elucidation of impurity was achieved by liquid chromatography hyphenated to different high resolution mass analyzers. Based on exact mass measurements and fragmentation pattern, a chloro alkyl carbonate ester analogue of the intermediate was identified. Structure of the impurity was confirmed by mass spectro-metric and NMR analyses of the target substance. Identified impurity could represent a hazard if it is transferred to the final API stage and its presence should be kept below allowed limits. Further investigation could reveal whether bis(1-chloroethyl) carbonate is a precursor to impurity formation. Therefore, synthesis should be regulated so as to minimize impurity production. Analysis of the final product indicated that the amount of impurity did not exceed 50 mg L−1, which represents the detection limit, determined according to the signal/noise ratio.

Parole chiave

  • candesartan cilexetil (TCV-116)
  • diastereoisomers
  • synthesis
  • impurity
  • HRMS
Accesso libero

Effects of annexin A1 on apoptosis and cell cycle arrest in human leukemic cell lines

Pubblicato online: 07 Dec 2018
Pagine: 75 - 86

Astratto

Abstract

Recent studies suggest that annexin A1 (ANXA1) promotes apoptosis in cancerous cells. This study aims to investigate the effects of ANXA1 on apoptosis and cell cycle arrest in K562, Jurkat and U937 cells and peripheral blood mononu-clear cells (PBMC). Cells were treated with ANXA1 and cyclophosphamide prior to flow cytometry analysis for apoptosis and cell cycle arrest induction. At 2.5µM, ANXA1 induced significant apoptosis in K562 (p ≤ 0.001) and U937 (p ≤ 0.05) cells, with EC50 values of 3.6 and 3.8 µM, respectively. In Jurkat cells, induction was not significant (EC50, 17.0 µM). No significant apoptosis induction was observed in PBMC. ANXA1 caused cycle arrest in the G0/G1 phase in K562 and U937 cells with p ≤ 0.001 for both, and (p ≤ 0.01) for Jurkat cells. ANXA1 induced apoptosis and cycle arrest in the G0/G1 phase in K562 and U937 cells, causing only cell cycle arrest in Jurkat cells.

Parole chiave

  • annexin A1
  • apoptosis
  • cell cycle
  • flow cytometry
  • human leukemic cell lines
Accesso libero

Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols

Pubblicato online: 07 Dec 2018
Pagine: 87 - 97

Astratto

Abstract

Despite growing prevalence of ovarian cancer (OC) in Pakistan, no literature evidence exists regarding its clinic-pathological characteristics, survival and compliance of patients with recurrent ovarian cancer on various chemo-protocols. An observational study was conducted by enrolling 251 recurrent OC patients on 7 different chemo-protocols, from a specialized cancer care hospital, Lahore, Pakistan, using convenient judgmental sampling. The study was conducted for a period of 6 months. Most of the patients were between 18 and 70 years of age, with IIIC FIGO stage and papillary serous histological grade. As per RECIST, improved partial response (PR) (63.3 %) and complete response (CR) (52.1 %) was observed in the CP (carboplatin + paclitaxel) arm, substantiated by improved median progression free survival (PFS) and overall survival (OS) in CP and CD (carboplatin + docetaxel) arms, respectively, yet with no significant differences in survival curves, PFS (p = 0.12) and OS (p = 0.22). Interestingly, the highest and the lowest patient non-compliance were observed in CG (carboplatin + gemcitabine) (81.6 %) and paclitaxel (4.5 %) arms, resp. As per the hazard model for survival, topotecan showed significant association with the therapy related events/deaths compared to other protocols. These data suggest that CP regimen exhibited improved clinical efficacy and decreased toxicity related non-compliance in recurrent ovarian cancer patients of Lahore.

Parole chiave

  • ovarian cancer
  • carboplatin plus paclitaxel
  • topotecan
  • bevacizumab
  • docetaxel
Accesso libero

Gellan gum and polyvinylpyrrolidone (PVP) as binding agents in extrusion/spheronization pellet formulations

Pubblicato online: 07 Dec 2018
Pagine: 99 - 109

Astratto

Abstract

The aim of this work was to evaluate gellan gum as binder in pellet formulations, with theophylline as the model drug, in comparison with polyvinylpyrrolidone (PVP). A full 32 factorial design was realized, with binder and diluent factors at three levels each. Pellets were produced by the extrusion/spheronization technique, and dried in a fluid-ized bed. Physical tests and dissolution tests were conducted. The results showed that the binder factor was not significant for pellet size and granulometry distribution. Rather, trends of a different response of gellan gum were identified, in comparison with PVP, in aspect ratio and dissolution tests: more round pellets were obtained in formulations with gellan gum, and more variable dissolution resulted when this polysaccharide was present. Therefore, if the usage of this compound in immediate release pellet formulations is verified, this justifies the interest in the development of sustained release systems using gellan gum.

Parole chiave

  • gellan gum
  • polyvinylpyrrolidone
  • pellets
  • extrusion
  • spheronization
Accesso libero

The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit of PI3Kγ

Pubblicato online: 07 Dec 2018
Pagine: 111 - 119

Astratto

Abstract

Umbelliferone exhibits extensive pharmacological activity, including anti-immunomodulatory, anti-inflammatory and antigenotoxicity activities. However, its antitumor properties still remain unclear in human renal cell carcinoma (RCC) cells. Our results have revealed that treatment of human RCC cells (786-O, OS-RC-2, and ACHN) with umbelliferone reduced cell proliferation in a concentration-dependent manner and induced dose-dependent apoptotic events. In addition, cell cycle analysis determined that umbelliferone treatment induced cell cycle arrest in the G1 phase in a dose-dependent manner. Furthermore, western blotting analysis showed a dose-dependent decrease in Ki67, MCM2, Bcl-2, CDK2, CyclinE1, CDK4, and CyclinD1 and a dose-dependent increase in Bax in RCC cells cultured with umbelliferone. Similarly, umbelliferone exhibited a dose-dependent reduction of p110γ when using western blotting analyses. Taken together, these results provide an insight into the pharmacology regarding the potential application of umbelliferone, which contributes to cell death by decreasing p110γ protein expression.

Parole chiave

  • umbelliferone
  • renal cell carcinoma
  • p110γ
  • anti-cancer activity
Accesso libero

Sesquiterpenes α-humulene and β-caryophyllene oxide enhance the efficacy of 5-fluorouracil and oxaliplatin in colon cancer cells

Pubblicato online: 07 Dec 2018
Pagine: 121 - 128

Astratto

Abstract

The present study is designed to find out if sesquiterpenes, α-humulene (HUM), valencene (VAL), β-caryphyllene-oxide (CAO) and trans-nerolidol (NER), are able to improve the antiproliferative effect of classical cytostatic drugs, 5-fluorouracil (FU) and oxaliplatin (1,2-diaminocyclohexaneoxalato-platinum, OxPt), in colon cancer cell lines Caco-2 and SW-620. In addition, the possible mechanisms of sesquiterpene action are studied. The results show significant ability of HUM and especially of CAO to enhance the anti-proliferative effects of FU and OxPt in cancer cell lines Caco-2 and SW-620. On the other hand, VAL and NER are ineffective. The action of CAO could be partly based on its ability to disrupt the mitochondrial membrane potential and to activate initiator caspases, but other mechanisms are probably also involved. Based on these results, CAO seems to have the potential for combination therapy of colon cancers and deserves further study.

Parole chiave

  • terpenes
  • Caco-2
  • SW-620
  • combination therapy
10 Articoli
Accesso libero

Pancreatic lipase inhibitory activity of selected pharmaceutical agents

Pubblicato online: 07 Dec 2018
Pagine: 1 - 16

Astratto

Abstract

Twenty-five structurally diverse compounds have been tested in vitro for their pancreatic lipase (PL) inhibitory activity. Despite the diversity of tested compounds, the relationship comprising structural attributes of the compounds could be established to correlate with the observed inhibitory activity. Compounds that exerted inhibitory action through surface activity were of different profile from the rest of compounds. When co-incubated with orlistat (OsT), important synergistic effects for some compounds (orphenadrine, gliclazide, cefuroxime and sulfacetamide) were revealed, while antagonistic effects were demonstrated for others (camphor sulfonic acid and dinitro salicylic acid). Docking studies for the most active molecules were performed and molecular interaction forces with the PL active site were identified. The results suggested co-binding of OsT along with the other inhibitor in the binding site in cases of synergistic effect but not in the case of antagonistic effect. These results were additionally supported by affinity capillary electrophoresis. In conclusion, synergistic lipase inhibitory activity between OsT and some other pharmaceutical compounds was demonstrated for the first time, which might help improve the pharmacological effect of OsT.

Parole chiave

  • pancreatic lipase
  • pancreatic lipase inhibitory test
  • pharmaceutical compounds
  • affinity capillary electrophoresis
  • docking studies
Accesso libero

Solubilization of ibuprofen for freeze dried parenteral dosage forms

Pubblicato online: 07 Dec 2018
Pagine: 17 - 32

Astratto

Abstract

Ibuprofen, a weakly acidic non-steroidal anti-inflammatory drug having poor aqueous solubility, is a challenging drug for the development of pharmaceutical formulations, resulting in numerous research attempts focusing on improvement of its solubility and consequently bioavailability. Most studies have been done for solid dosage forms, with very little attention paid to parenterals. Hence, the main purpose of the present study was to enhance ibuprofen solubility as a result of formulation composition and the freeze drying process. Moreover, the purpose was to prepare a freeze dried dosage form with improved ibuprofen solubility that could, after simple reconstitution with water for injection, result in an isotonic parenteral solution. Solubility of ibuprofen was modified by various excipients suitable for parenteral application. Drug interactions with selected excipients in the final product/lyophilisate were studied by a combined use of XRPD, DSC, Raman and ss-NMR. Analyses of lyophilized samples showed solubility enhancement of ibuprofen and in situ formation of an ibuprofen salt with the alkaline excipients used.

Parole chiave

  • ibuprofen
  • solubility enhancement
  • freeze drying
  • physicochemical characterization
Accesso libero

Therapeutic bullfrog oil-based nanoemulsion for oral application: Development, characterization and stability

Pubblicato online: 07 Dec 2018
Pagine: 33 - 48

Astratto

Abstract

The aim of this study was to develop, optimize, and characterize a stable therapeutic bullfrog oil based nanoemulsion for oral application using a rational experimental design approach. The optimized oral nanoemulsion contained 0.2 % sodium benzoate and 0.02 % propyl-paraben as preservatives; 0.1 % sucralose and 0.4 % acesulfam K as sweeteners and 0.1 % tutti-frutti as flavoring to mask the unpleasant organoleptic characteristics of bullfrog oil. The oral O/W-nanoemulsion showed the droplet size, PDI, zeta potential, and pH of 410 ± 8 nm, 0.20 ± 0.02, –38 ± 2.5 mV, and 6.43 ± 0.05, respectively. The optimized oral nanoemulsion showed a milky single-phase and optimal physical stability at 25 °C for 90 days. Indeed, higher oxidation induction time and lower formation of peroxides in the oral nanoemulsion were responsible for improving its stability. A therapeutic delivery system containing bullfrog oil for oral application was successfully developed and optimized with ideal thermo-oxidative stability.

Parole chiave

  • bullfrog oil
  • nanoemulsion
  • thermo-oxidative stability
  • experimental design
  • oral application
  • therapeutic nanosystem
Accesso libero

Dendrimer functionalized folate-targeted gold nanoparticles for luciferase gene silencing in vitro: A proof of principle study

Pubblicato online: 07 Dec 2018
Pagine: 49 - 61

Astratto

Abstract

Use of exogenous small interfering RNA (siRNA) has shown potential in gene silencing. The need for target-specific siRNA delivery vehicles is crucial to successful gene silencing. This study is aimed at developing and evaluating the safety and efficiency of siRNA delivery using unmodified and folic acid (FA) modified poly(amidoamine) generation 5 (PAMAM G5D) functionalized gold nanoparticles (Au:G5D/Au:G5D:FA) in vitro. All formulations were physico--chemically characterized and nanocomplexes were evaluated using the band shift, dye displacement, nuclease protection, MTT cell viability, and luciferase reporter gene assays. Nanocomplexes bound and protected siRNA against degrading RNases, and were well tolerated by the cells. The Au:G5D:FA nanocomplexes elicited excellent gene silencing in folate receptor expressing HeLa-Tat-Luc cells, decreasing significantly in the presence of excess FA ligand, indicating nanocomplex uptake by the mechanism of receptor mediation. These results highlight the synergistic role played by Au and the dendrimer in enhancement of transgene silencing.

Parole chiave

  • siRNA
  • gold nanoparticles
  • dendrimers
  • folic acid
  • gene silencing
Accesso libero

Identification of new process-related impurity in the key intermediate in the synthesis of TCV-116

Pubblicato online: 07 Dec 2018
Pagine: 63 - 74

Astratto

Abstract

Development of safe and effective drugs requires complete impurity evaluation and, therefore, knowledge about the formation and elimination of impurities is necessary. During impurity profiling of a key intermediate during synthesis of candesartan cilexetil (1-(((cyclohexyloxy)carbonyl) oxy)ethyl 1-((2’-(2H-tetrazol-5-yl)-[1,1’-biphenyl]-4-yl) methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate, TCV-116), a novel compound, which had not been reported previously, was observed. Structural elucidation of impurity was achieved by liquid chromatography hyphenated to different high resolution mass analyzers. Based on exact mass measurements and fragmentation pattern, a chloro alkyl carbonate ester analogue of the intermediate was identified. Structure of the impurity was confirmed by mass spectro-metric and NMR analyses of the target substance. Identified impurity could represent a hazard if it is transferred to the final API stage and its presence should be kept below allowed limits. Further investigation could reveal whether bis(1-chloroethyl) carbonate is a precursor to impurity formation. Therefore, synthesis should be regulated so as to minimize impurity production. Analysis of the final product indicated that the amount of impurity did not exceed 50 mg L−1, which represents the detection limit, determined according to the signal/noise ratio.

Parole chiave

  • candesartan cilexetil (TCV-116)
  • diastereoisomers
  • synthesis
  • impurity
  • HRMS
Accesso libero

Effects of annexin A1 on apoptosis and cell cycle arrest in human leukemic cell lines

Pubblicato online: 07 Dec 2018
Pagine: 75 - 86

Astratto

Abstract

Recent studies suggest that annexin A1 (ANXA1) promotes apoptosis in cancerous cells. This study aims to investigate the effects of ANXA1 on apoptosis and cell cycle arrest in K562, Jurkat and U937 cells and peripheral blood mononu-clear cells (PBMC). Cells were treated with ANXA1 and cyclophosphamide prior to flow cytometry analysis for apoptosis and cell cycle arrest induction. At 2.5µM, ANXA1 induced significant apoptosis in K562 (p ≤ 0.001) and U937 (p ≤ 0.05) cells, with EC50 values of 3.6 and 3.8 µM, respectively. In Jurkat cells, induction was not significant (EC50, 17.0 µM). No significant apoptosis induction was observed in PBMC. ANXA1 caused cycle arrest in the G0/G1 phase in K562 and U937 cells with p ≤ 0.001 for both, and (p ≤ 0.01) for Jurkat cells. ANXA1 induced apoptosis and cycle arrest in the G0/G1 phase in K562 and U937 cells, causing only cell cycle arrest in Jurkat cells.

Parole chiave

  • annexin A1
  • apoptosis
  • cell cycle
  • flow cytometry
  • human leukemic cell lines
Accesso libero

Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols

Pubblicato online: 07 Dec 2018
Pagine: 87 - 97

Astratto

Abstract

Despite growing prevalence of ovarian cancer (OC) in Pakistan, no literature evidence exists regarding its clinic-pathological characteristics, survival and compliance of patients with recurrent ovarian cancer on various chemo-protocols. An observational study was conducted by enrolling 251 recurrent OC patients on 7 different chemo-protocols, from a specialized cancer care hospital, Lahore, Pakistan, using convenient judgmental sampling. The study was conducted for a period of 6 months. Most of the patients were between 18 and 70 years of age, with IIIC FIGO stage and papillary serous histological grade. As per RECIST, improved partial response (PR) (63.3 %) and complete response (CR) (52.1 %) was observed in the CP (carboplatin + paclitaxel) arm, substantiated by improved median progression free survival (PFS) and overall survival (OS) in CP and CD (carboplatin + docetaxel) arms, respectively, yet with no significant differences in survival curves, PFS (p = 0.12) and OS (p = 0.22). Interestingly, the highest and the lowest patient non-compliance were observed in CG (carboplatin + gemcitabine) (81.6 %) and paclitaxel (4.5 %) arms, resp. As per the hazard model for survival, topotecan showed significant association with the therapy related events/deaths compared to other protocols. These data suggest that CP regimen exhibited improved clinical efficacy and decreased toxicity related non-compliance in recurrent ovarian cancer patients of Lahore.

Parole chiave

  • ovarian cancer
  • carboplatin plus paclitaxel
  • topotecan
  • bevacizumab
  • docetaxel
Accesso libero

Gellan gum and polyvinylpyrrolidone (PVP) as binding agents in extrusion/spheronization pellet formulations

Pubblicato online: 07 Dec 2018
Pagine: 99 - 109

Astratto

Abstract

The aim of this work was to evaluate gellan gum as binder in pellet formulations, with theophylline as the model drug, in comparison with polyvinylpyrrolidone (PVP). A full 32 factorial design was realized, with binder and diluent factors at three levels each. Pellets were produced by the extrusion/spheronization technique, and dried in a fluid-ized bed. Physical tests and dissolution tests were conducted. The results showed that the binder factor was not significant for pellet size and granulometry distribution. Rather, trends of a different response of gellan gum were identified, in comparison with PVP, in aspect ratio and dissolution tests: more round pellets were obtained in formulations with gellan gum, and more variable dissolution resulted when this polysaccharide was present. Therefore, if the usage of this compound in immediate release pellet formulations is verified, this justifies the interest in the development of sustained release systems using gellan gum.

Parole chiave

  • gellan gum
  • polyvinylpyrrolidone
  • pellets
  • extrusion
  • spheronization
Accesso libero

The antitumor activity of umbelliferone in human renal cell carcinoma via regulation of the p110γ catalytic subunit of PI3Kγ

Pubblicato online: 07 Dec 2018
Pagine: 111 - 119

Astratto

Abstract

Umbelliferone exhibits extensive pharmacological activity, including anti-immunomodulatory, anti-inflammatory and antigenotoxicity activities. However, its antitumor properties still remain unclear in human renal cell carcinoma (RCC) cells. Our results have revealed that treatment of human RCC cells (786-O, OS-RC-2, and ACHN) with umbelliferone reduced cell proliferation in a concentration-dependent manner and induced dose-dependent apoptotic events. In addition, cell cycle analysis determined that umbelliferone treatment induced cell cycle arrest in the G1 phase in a dose-dependent manner. Furthermore, western blotting analysis showed a dose-dependent decrease in Ki67, MCM2, Bcl-2, CDK2, CyclinE1, CDK4, and CyclinD1 and a dose-dependent increase in Bax in RCC cells cultured with umbelliferone. Similarly, umbelliferone exhibited a dose-dependent reduction of p110γ when using western blotting analyses. Taken together, these results provide an insight into the pharmacology regarding the potential application of umbelliferone, which contributes to cell death by decreasing p110γ protein expression.

Parole chiave

  • umbelliferone
  • renal cell carcinoma
  • p110γ
  • anti-cancer activity
Accesso libero

Sesquiterpenes α-humulene and β-caryophyllene oxide enhance the efficacy of 5-fluorouracil and oxaliplatin in colon cancer cells

Pubblicato online: 07 Dec 2018
Pagine: 121 - 128

Astratto

Abstract

The present study is designed to find out if sesquiterpenes, α-humulene (HUM), valencene (VAL), β-caryphyllene-oxide (CAO) and trans-nerolidol (NER), are able to improve the antiproliferative effect of classical cytostatic drugs, 5-fluorouracil (FU) and oxaliplatin (1,2-diaminocyclohexaneoxalato-platinum, OxPt), in colon cancer cell lines Caco-2 and SW-620. In addition, the possible mechanisms of sesquiterpene action are studied. The results show significant ability of HUM and especially of CAO to enhance the anti-proliferative effects of FU and OxPt in cancer cell lines Caco-2 and SW-620. On the other hand, VAL and NER are ineffective. The action of CAO could be partly based on its ability to disrupt the mitochondrial membrane potential and to activate initiator caspases, but other mechanisms are probably also involved. Based on these results, CAO seems to have the potential for combination therapy of colon cancers and deserves further study.

Parole chiave

  • terpenes
  • Caco-2
  • SW-620
  • combination therapy

Pianifica la tua conferenza remota con Sciendo